HealthQuill Biosimilars
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug Administration.
Drugs Health Pharma

US drug regulator clears Amgen’s biosimilar to treat rare blood disorder

The US drug regulator has approved Amen’s biosimilar, Bkemv,  to treat rare blood disorders, according to a statement from the Food and Drug.

Read More
Biocon
Drugs Pharma

Biocon signs out-licencing pact with Yoshindo

HQ Team October 17, 2022: Biocon Biologics, a subsidiary of India’s Biocon, has inked an out-licencing pact with Japan’s Yoshindo Inc for selling.

Read More
X